How CGRP Went from Obscure Peptide to Revolutionary Migraine Drug Target
Decades of research proved CGRP is a key driver of migraine pain, leading to two new drug classes — injectable antibodies and oral gepants — that have transformed migraine treatment.
Quick Facts
What This Study Found
CGRP (calcitonin gene-related peptide) has been definitively proven as a central driver of migraine through decades of converging evidence: anatomical colocalization with pain-producing meningeal blood vessels, elevated levels during migraine attacks, intravenous CGRP triggering migraines only in migraineurs, and clinical efficacy of drugs blocking CGRP.
Critically, PET imaging studies showed that CGRP receptor antagonists achieved no brain receptor occupancy at effective antimigraine doses — proving the therapeutic action is peripheral, not central. This revolutionized migraine understanding: migraine pain is at least partly peripheral in origin.
Two drug classes have emerged from this science: (1) monoclonal antibodies given by injection that neutralize CGRP peptide (fremanezumab, galcanezumab, eptinezumab) or block its receptor (erenumab) for migraine prevention; and (2) oral small-molecule CGRP receptor antagonists (gepants) for both acute treatment (ubrogepant, rimegepant) and prevention (atogepant). All have shown consistent efficacy in large, multicenter RCTs.
Key Numbers
4 approved anti-CGRP antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) · 3 approved gepants (ubrogepant, rimegepant, atogepant) · PET showed 0 brain receptor occupancy at effective doses · IV CGRP triggers migraine only in migraineurs
How They Did This
Comprehensive narrative review published in Headache, the official journal of the American Headache Society. Chronicles the scientific history of CGRP in migraine from anatomical discovery through translational studies, clinical trials of small molecule antagonists, PET imaging proof-of-mechanism, and the development and approval of anti-CGRP antibodies and gepants.
Why This Research Matters
The CGRP migraine story is one of the greatest successes in peptide-based drug development. It took the field from a peptide discovered in sensory nerves to multiple FDA-approved drugs in two different drug classes — all within a few decades. This represents a complete bench-to-bedside arc: peptide biology → disease mechanism → drug target → approved therapeutics. It also fundamentally changed how scientists understand migraine — from a brain disorder to one with a significant peripheral peptide component.
The Bigger Picture
The CGRP-migraine story is a template for how peptide science can transform medicine. A peptide identified through basic neuroscience research became the basis for an entirely new class of drugs that have improved the lives of millions of migraine sufferers. The approach — targeting a specific neuropeptide pathway with both biologics and small molecules — is now being applied to other pain conditions and could serve as a model for future peptide drug development.
What This Study Doesn't Tell Us
Published in 2019, so does not cover the most recent clinical data and real-world experience with anti-CGRP drugs. As a review by key figures in the field, it presents an advocacy perspective for CGRP-based approaches. Long-term safety data for anti-CGRP therapies was still limited at time of publication.
Questions This Raises
- ?What are the long-term effects of chronically blocking CGRP, given its roles in cardiovascular protection and wound healing?
- ?Will newer CGRP-targeting approaches (like combination therapies or dual-mechanism drugs) further improve migraine outcomes?
- ?Can the CGRP drug development model be replicated for other neuropeptide-driven conditions like cluster headache or fibromyalgia?
Trust & Context
- Key Stat:
- 7+ approved drugs CGRP-targeting therapies include 4 injectable antibodies and 3 oral gepants — all developed from the discovery that this single peptide drives migraine pain
- Evidence Grade:
- Published in Headache by leaders in the field. The review synthesizes evidence from multiple large, multicenter RCTs, PET imaging studies, and translational research. The clinical efficacy of CGRP-targeting drugs is supported by the highest level of evidence — multiple randomized, placebo-controlled trials leading to FDA approval.
- Study Age:
- Published in 2019. All major anti-CGRP drugs discussed were approved at or around the time of publication. The field has since expanded with additional real-world data and new indications.
- Original Title:
- Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
- Published In:
- Headache, 59(6), 951-970 (2019)
- Authors:
- Hargreaves, Richard, Olesen, Jes
- Database ID:
- RPEP-04223
Evidence Hierarchy
Frequently Asked Questions
What is CGRP and why does it cause migraines?
CGRP (calcitonin gene-related peptide) is a neuropeptide released by sensory nerve fibers around the brain's blood vessels. During a migraine, CGRP levels spike, causing blood vessel dilation, inflammation, and pain signaling. Blocking CGRP — either by neutralizing the peptide or blocking its receptor — stops or prevents migraines in most patients.
What's the difference between anti-CGRP antibodies and gepants?
Anti-CGRP antibodies (Aimovig, Ajovy, Emgality) are injectable drugs given monthly or quarterly for migraine prevention. Gepants (ubrogepant, rimegepant, atogepant) are oral pills that can treat migraines acutely or prevent them when taken daily. Both target the same CGRP pathway but through different mechanisms — antibodies neutralize the peptide or block the receptor long-term, while gepants provide shorter-duration receptor blockade.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04223APA
Hargreaves, Richard; Olesen, Jes. (2019). Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.. Headache, 59(6), 951-970. https://doi.org/10.1111/head.13510
MLA
Hargreaves, Richard, et al. "Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.." Headache, 2019. https://doi.org/10.1111/head.13510
RethinkPeptides
RethinkPeptides Research Database. "Calcitonin Gene-Related Peptide Modulators - The History and..." RPEP-04223. Retrieved from https://rethinkpeptides.com/research/hargreaves-2019-calcitonin-generelated-peptide-modulators
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.